Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfizer Research & Development GPR61 compound 15: sourced facts only. name: "The cryogenic electron microscopy structure of GPR61 bound to compound 15 shows that this class of inverse agonists binds to an induced, intracellular, allosteric pocket and abolishes GPR61 constitutive activity by disrupting its interactions with G protein, representing a novel mode of action of GPCR inverse agonism." [PMID:41834467]; target: "The cryogenic electron microscopy structure of GPR61 bound to compound 15 shows that this class of inverse agonists binds to an induced, intracellular, allosteric pocket and abolishes GPR61 constitutive activity by disrupting its interactions with G protein, representing a novel mode of action of GPCR inverse agonism." [PMID:41834467]; developer: "Pfizer Research & Development, 558 Eastern Point Rd, Groton, Connecticut 06340, United States." [PMID:41834467]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pfizer Research & Development GPR61 compound 15.